Insulin resistance: What is its role in the polycystic ovary syndrome?

Current Opinion in Endocrinology and Diabetes

Volumn 9, Issue 6, 2002, Pages 444-450

  Moghetti, Paolo ^a,b  

^a UNIVERSITY OF VERONA   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANDROGEN; ARGININE; C REACTIVE PROTEIN; CALPAIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYSTEINE PROTEINASE; ENDOTHELIN 1; FATTY ACID; GLYCINE; HYDROXYPROGESTERONE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 2; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE; PRASTERONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANDROGEN RELEASE; ANOVULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENVIRONMENT; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC POLYMORPHISM; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART INFARCTION; HIRSUTISM; HORMONE ACTION; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOTHESIS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPOLYSIS; LIVER TOXICITY; MENSTRUAL IRREGULARITY; MICROSATELLITE MARKER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; PANCREAS ISLET BETA CELL; PATHOGENESIS; PHENOMENOLOGY; PHENOTYPE; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; STEROIDOGENESIS;

EID: 0038687067     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200212000-00002     Document Type: Review

References (88)

1. Dunaif A: Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997, 18:774-800.
2. Nestler JE: Insulin resistance and the polycystic ovary syndrome: recent advances. Curr Opin Endocrinol Diabetes 2000, 7:345-349.
3. Ovesen P, Moller J, Ingerslev HJ, et al.: Normal basal and insulin-stimulated fuel metabolism in lean women with polycystic ovary syndrome. J Clin Endocrinol Metab 1993, 77:1636-1640.
4. Holte J, Bergh T, Berne C, et al.: Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 1994, 78:1052-1058.
5. Holte J: Polycystic ovary syndrome and insulin resistance: thrifty genes struggling with over-feeding and sedentary life style? J Endocrinol Invest 1998, 21:589-601.
6. Zawadzki JK, Dunaif A: Diagnostic criteria for Polycystic Ovary Sindrome: towards a rational approach. In Polycystic Ovary Syndrome. Edited by Dunaif A, Givens JR, Haseltine FP, et al. Boston: Blackwell Scientific Publications; 1992:377-384.
7. Barbieri RL, Makris A, Randall RW, et al.: Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab 1986, 62:904-910.
8. Poretsky L: On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991, 12:3-13.
9. Moghetti P, Castello R, Negri C, et al.: Insulin infusion amplifies 17α-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 1996, 81:881-886.
10. Nestler JE, Powers LP, Matt DW: A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991, 72:83-89.
11. Ehrmann D, Sturis J, Byrne M, et al.: Insulin secretory defects in polycystic ovary syndrome: relation to insulin sensitivity and family history of non-insulin dependent diabetes mellitus. J Clin Invest 1995, 96:520-527.
12. Kulkarni RN, Bruning JC, Winnay JN, et al.: Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999, 96:329-339.
13. Marchetti P, Lui R, Federici M, et al.: Insulin secretory function is impaired in isolated human islets carrying the Gly(972)·Arg IRS-1 polymorphism. Diabetes 2002, 51:1419-1424.
14. Rosenfield RL: Evidence that idiopathic functional adrenal hyperandrogenism is caused by dysregulation of adrenal steroidogenesis and that hyperinsulinemia may be involved. J Clin Endocrinol Metab 1996, 81:878-880.
15. Moghetti P, Tosi F, Castello R, et al.: The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996, 81:952-960.
16. Holmang A, Svedberg J, Jennische E, et al.: Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 1990, 259:E555-E560.
17. Speiser PW, Serrat J, New MI, et al.: Insulin insensitivity in adrenal hyperplasia due to nonclassical steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1992, 75:1421-1424.
18. Dunaif A, Xia J, Book CB, et al.: Excessive insulin receptor serine phosphorylation in cultured fibroblast and skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 1995, 96:801-810.
19. Waterworth DM, Bennett ST, Gharani N, et al.: Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet 1997, 349:986-990.
20. Urbanek M, Legro RS, Driscoll DA, et al.: Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proc Natl Acad Sci 1999, 96:8573-8578.
21. Pasquali R, Antenucci D, Casimirri F, et al.: Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989, 68:173-179.
22. Kiddy DS, Hamilton-Fairley D, Bush A, et al.: Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol 1992, 36:105-111.
23. Nestler JE, Barlascini CO, Matt DW, et al.: Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989, 68:1027-1032.
24. Prelevic GM, Wurzburger MI, Balint-Peric L, et al.: Inhibitory effect of sandostatin on luteinizing hormone and ovarian steroids in polycystic ovary syndrome. Lancet 1990, 336:900-903.
25. Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome P450c17 activity and serum free testosterone after reduction in insulin secretion in polycystic ovary syndrome. N Engl J Med 1996, 335:617-623.
26. Moghetti P, Castello R, Negri C, et al.: Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long term clinical evaluation. J Clin Endocrinol Metab 2000, 85:139-146.
27. Azziz R, Ehrmann D, Legro RS, et al.: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2001, 86:1626-1632.
28. Nestler JE, Jakubowicz DJ, Reamer P, et al.: Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999, 340:1314-1320.
29. DeFronzo RA, Ferrannini E: Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14:173-194.
30. Haffner SM, Valdez RA, Hazuda HP, et al.: Prospective analysis of the insulin resistance syndrome (syndrome X). Diabetes 1992, 41:715-722.
31. Dahlgren E, Janson PO, Johansson S, et al.: Polycystic ovary syndrome and risk for myocardial infarction. Acta Obstet Gynecol Scand 1992, 71:599-603.
32. Legro RS, Kunselman AR, Dodson WC, et al.: Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999, 84:165-169.
33. Ehrmann DA, Barnes RB, Rosenfield RL, et al.: Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999, 22:141-146.
34. Norman RJ, Masters L, Milner CR, et al.: Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001, 16:1995-1998. Prospective data on risk of abnormalities in glucose tolerance of women with PCOS are very limited. This study shows a marked increase of risk in young, mildly overweight Caucasian subjects.
35. Arslanian SA, Lewy V, Danadian K, et al.: Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002, 87:1555-1559.
36. Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002, 346:393-403.
37. Conn JJ, Jacobs HS, Conway GS: The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol 2000, 52:81-86.
38. Peppard HR, Marfori J, Iuorno MJ, et al.: Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 2001, 24:1050-1052.
39. Moghetti P: Advances in the treatment of polycystic ovary syndrome. Expert Opin Investig Drugs 2001, 10:1631-1640.
40. Jakubowicz DJ, Iourno MJ, Jakubowicz S, et al.: Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:524-529. This study suggests a striking reduction in the risk of early pregnancy loss in PCOS subjects given metformin throughout pregnancy, suggesting that insulin resistance might also be important in post-conceptional events. These data need to be confirmed by controlled trials.
41. Glueck CJ, Phillips H, Cameron D, et al.: Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001, 75:46-52.
42. Jakubowicz DJ, Seppala M, Jakubowicz S, et al.: Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 2001, 86:1126-1133.
43. Arlt W, Auchus RJ, Miller WL: Thiazoledinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3beta-hydroxysteroid dehydrogenase. J Biol Chem 2001, 276:16767-16771.
44. Veldhuis JD, Zhang G, Garmey JC: Troglitazone, an insulin-sensitizing thiazolidinedione, represses combined stimulation by LH and insulin of de novo androgen biosynthesis by thecal cells in vitro. J Clin Endocrinol Metab 2002, 87:1129-1133.
45. Mitwally MF, Witchel SF, Casper RF: Troglitazone: a possible modulator of ovarian steroidogenesis. J Soc Gynecol Investig 2002, 9:163-167.
46. Montague CT, O'Rahilly S: The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000, 49:883-888.
47. Ek I, Arner P, Ryden M, et al.: A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 2002, 51:484-492. This study reports that women with PCOS have abnormal postreceptor sensitivity to catecholamines in visceral fat cells, because of dysfunction of PKA-dependent hormone-sensitive lipase. This defect differed from alterations at the adrenoceptor level found in the metabolic syndrome.
48. Hoffstedt J, Wahrenberg H, Thorne A, et al.: The metabolic syndrome is related to beta-adrenoreceptor sensitivity in visceral adipose tissue. Diabetologia 1996, 39:838-844.
49. Poretsky L, Seto-Young D, Shrestha A, et al.: Phosphatidyl-inositol-3 Kinase-independent insulin action pathway(s) in the human ovary. J Clin Endocrinol Metab 2001, 86:3115-3119. This study supports the hypothesis of distinct pathways of insulin signaling involved in regulation of ovarian steroidogenesis and glucose metabolism.
50. Dunaif A, Wu X, Lee A, et al.: Defects in insulin receptor signaling in vivo in the polycysic ovary syndrome (PCOS). Am J Physiol Endocrinol Metab 2001, 281:E392-399. This study provides evidence of impaired in vivo stimulation by insulin of phosphatidyl-inositol-3 kinase activity in skeletal muscle. This defect could be involved in resistance to insulin action on glucose metabolism commonly found in these women.
51. Carey AH, Waterworth D, Patel K, et al.: Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994, 3:1873-1876.
52. Gharani N, Waterworth D, Williamson R, et al.: 5′ polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J Clin Endocrinol Metab 1996, 91:4174.
53. Urbanek M, Wu X, Vickery KR, et al.: Allelic variants of the follistatin gene in polycystic ovary syndrome. J Clin Endocrinol Metab 2000, 85:4455-4461.
54. Michelmore K, Ong K, Mason S, et al.: Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol 2001, 55:439-446.
55. Calvo RM, Telleria D, Sancho J, et al.: Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women. Fertil Steril 2002, 77:666-668.
56. Baier LJ, Permana PA, Yang X, et al.: A calpain-10 gene polymorphism is associated with reduced muscle mRNA levels and insulin resistance. J Clin Invest 2000, 106:R69-R73.
57. Horikawa Y, Oda N, Cox NJ, et al.: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet 2000, 26:163-175.
58. Ehrmann DA, Schwarz PEH, Hara M, et al.: Relation of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:1669-1673.
59. Escobar-Morreale HF, Peral B, Villuendas G, et al.: Common single nucleotide polymorphisms in intron 3 of the Calpain-10 gene influence hirsutism. Fertil Steril 2002, 77:581-587.
60. Haddad L, Evans JC, Gharani N, et al.: Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:2606-2610.
61. Kahn CR, Flier JS, Bar RS, et al.: The syndromes of insulin resistance and acanthosis nigricans. N Engl J Med 1976, 294:739-745.
62. Hitman GA, Hawrami K, McCarthy MI et al.: Insulin receptor substrate-1 gene mutation in NIDDM: implications for the study of polygenic diseases. Diabetologia 1995, 38:481-486.
63. Almind K, Inone G, Pedersen O, et al.: A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transfection studies. J Clin Invest 1996, 97:2569-2575.
64. Talbot JA, Bicknell EJ, Rajkhowa M, et al.: Molecular scanning of the insulin receptor gene in the women with polycystic ovarian syndrome J Clin Endocrinol Metab 1996, 81:1979-1983.
65. Sir-Petermann T, Perez-Bravo F, Angel B, et al.: G972R polymorphism of IRS-1 in women with polycystic ovary syndrome. Diabetologia 2001, 44:1200-1201.
66. El Mkadem SA, Lautier C, Macari F, et al.: Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes 2001, 50:2164-2168.
67. Tucci S, Futterweit W, Concepcion ES, et al.: Evidence for association of polycystic ovary syndrome in Caucasian women with a marker at the insulin receptor gene locus. J Clin Endocrinol Metab 2001, 86:446-449.
68. Villuendas G, Escobar-Morreale HF, Tosi F, et al.: The D19S884 marker at the insulin receptor gene locus and the polycystic ovary syndrome. Fertil Steril 2002 (in press).
69. Legro RS, Bentley-Lewis R, Driscoll D, et al.: Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity. J Clin Endocrinol Metab 2002, 87:2128-2133. This study assessed characteristics of PCOS sisters, reporting that markers of insulin resistance are associated with hyperandrogenemia rather than menstrual abnormalities. Increased serum androgens could be an early marker of metabolic abnormalities and propensity to cardiovascular risk in these women.
70. Carmina E, Lobo R: Polycystic ovaries in hirsute women with normal menses. Am J Med 2001, 111:602-606.
71. Legro RS, Kunselman AR, Demers L, et al.: Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:2134-2138.
72. Nestler JE, Whitfield JB, Williams TY, et al.: Genetics of serum dehydroepiandrosterone sulfate and its relation to insulin in a population-based cohort of twin subjects. J Clin Endocrinol Metab 2002, 87:682-686.
73. Guzick DS, Talbott EO, Sutton-Tyrrell K, et al.: Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. Am J Obstet Gynecol 1996, 174:1224-1232.
74. Birdsall MA, Farquhar CM, White HD: Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997, 126:32-35.
75. Cibula D, Cifkova R, Fanta M, et al.: Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000, 15:785-789.
76. Wild S, Pierpont T, McKeigue P, et al.: Cardiovascular disease in women with PCOS at long-term follow-up: a retrospective cohort study. Clin Endocrinol 2000, 52:595-600.
77. Solomon CG, Hu FB, Dunaif A, et al.: Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002, 87:2013-2017. This is the first study showing that women with PCOS might have increased cardiovascular mortality. Diagnosis was presumed by menstrual abnormalities.
78. Kelly CJG, Speirs A, Gould GW, et al.: Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002, 87:742-746. This study assessed macro- and micro-vascular functions in PCOS, suggesting early changes in muscle structure of arterial wall and impaired insulin sensitivity of endothelium.
79. Paradisi G, Steimberg H, Hempfling A, et al.: Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001, 103:1410-1415.
80. Mather KJ, Verna S, Corenblum B, et al.: Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome. J Clin Endocrinol Metab 2000, 85:1851-1856.
81. Zeng G, Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996, 98:894-898.
82. Kelly CJG, Lyall H, Petrie JR, et al.: Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001, 86:2453-2455.
83. Yudkin JS, Stehouwer CD, Emeis JJ, et al.: C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999, 19:972-978.
84. Ridker PM, Hennekens CH, Buring JE, et al.: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
85. Lagrand WK, Visser CA, Hermens WT, et al.: C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999, 100:96-102.
86. Diamanti-Kandarakis E, Spina G, Kouli C, et al.: Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001, 86:4666-4673. This study reports evidence of a striking increase in serum endothelin-1, a vasoconscrictive substance, in PCOS. Interestingly, this alteration was improved by metformin treatment.
87. Hopfner RL, Gopalakrishnan V: Endothelin: emerging role in diabetic vascular complications. Diabetologia 1999, 42:1383-1394.
88. Ferri C, Bellini C, Desideri G, et al.: Elevated plasma endothelin-1 levels as an additional risk factor in non-obese essential hypertensive patients with metabolic abnormalities. Diabetologia 1997, 40:100-102.